BeyondSpring Inc.
No SEC Form 4 filings for $BYSI in the last 30 days.
See all $BYSI insider activity →BeyondSpring Inc. (BYSI) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On September 28, 2026, BeyondSpring Inc. (“BYSI” or the “Company”) entered into a Share Purchase and Collaboration Agreement (the “Agreement”) with Dalian Wanchunbulin Pharmaceuticals Ltd. (“Bulin”), a
BeyondSpring Inc. (BYSI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EXHIBIT 99.1 BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis FDA Fast Track designation represents an important regulatory milestone
BeyondSpring Inc. (BYSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibito
Over the past 7 days, AlphAI's AI scored 1 news story mentioning BYSI (BeyondSpring Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent BYSI coverage spans financial news, mergers & acquisitions and corporate actions.
The asset sale removes revenue‑generating businesses and may reduce future cash flow, likely pressuring the stock.
Regulatory approval and non‑dilutive financing reduce cash burn and de‑risk the Phase 3 program, likely supporting share‑price upside.
The filing adds fresh clinical efficacy context for Plinabulin’s confirmatory Phase 3 (DUBLIN-4) while highlighting cash burn and a leadership/CFO change tied to financing and regulatory prep.
Board/exec restructuring is intended to accelerate DUBLIN-4 execution and strengthen capital-market readiness ahead of key clinical milestones.
Insider ownership reports indicate substantial holdings by key executives, suggesting confidence in the company's prospects. This could lead to increased investor interest and potential upward price movement.
AlphAI scores every news story that mentions BYSI with an AI model for sentiment and relevance, and aggregates insider trades from BeyondSpring Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BeyondSpring Inc. (BYSI) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On September 28, 2026, BeyondSpring Inc. (“BYSI” or the “Company”) entered into a Share Purchase and Collaboration Agreement (the “Agreement”) with Dalian Wanchunbulin Pharmaceuticals Ltd. (“Bulin”), a
2 min readBeyondSpring Inc. (BYSI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EXHIBIT 99.1 BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis FDA Fast Track designation represents an important regulatory milestone
2 min readBeyondSpring Inc. (BYSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibito
6 min readBeyondSpring Inc. (NASDAQ: BYSI) announced a leadership transition effective July 1, 2026. Dr. Lan Huang will remain Chairman; Dr. Jiangwen (Jen) Majeti becomes Vice Chairman; Min Qiu is appointed CEO to execute the confirmatory DUBLIN-4 Phase 3 trial of Plinabulin plus docetaxel; and Na Li becomes CFO to strengthen the company’s financial position and capital markets engagement.
6 min readBeyondSpring Inc. (BYSI) insiders Lan Huang and Linqing Jia each reported beneficial ownership of 5,787,906 shares, representing 14.1% of the company's outstanding shares as of March 31, 2026. This disclosure was made in an Amendment No. 9 to a Schedule 13G/A filing, detailing ownership through various entities, trusts, and proxies, and clarifying shared voting and dispositive powers. The filing also revealed recent intra-family trust transfers of 260,582 and 253,465 shares.
2 min readBeyondSpring (NASDAQ: BYSI) reported a consolidated net loss of $6.7 million for Q1 2026, a significant swing from a $1.2 million net income in Q1 2025, primarily due to a $4.3 million loss from discontinued SEED operations and the absence of a $7.0 million gain from a SEED share sale seen in the prior year. The company's continuing operations recorded a $2.4 million net loss, with research and development expenses increasing while general and administrative costs decreased. BeyondSpring ended the quarter with $7.9 million in cash and short-term investments from continuing operations, and expects additional inflows from future SEED preferred share sales, with management exploring various financing and strategic alternatives.
4 min readBeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company, announced that it will present a poster on Plinabulin and ADC combination at the 2026 AACR Annual Meeting. The presentation, titled "Plinabulin Boosts Antitumor Efficacy of Topoisomerase Inhibitor-based Antibody-drug Conjugates Without or With Immune Checkpoint Inhibitor," will detail how Plinabulin enhances the effectiveness of antibody-drug conjugates. This aims to highlight its potential in improving cancer treatment outcomes, particularly in restoring tumor sensitivity to checkpoint inhibitors.
2 min readFLORHAM PARK, N.J., May 12, 2025 ( GLOBE NEWSWIRE ) -- BeyondSpring Inc. ( NASDAQ: BYSI ) , a clinical‑stage global biopharmaceutical company focused on developing cancer therapeutics, today announced its unaudited financial results for the quarter ended March 31, 2025, and provided a corporate ...
2 min read
